Amphista Therapeutics, AMX-883, Acute Myeloid Leukemia, AML, Myelodysplastic Syndrome, MDS, Phase 1 Clinical Trial, BRAMLIE Trial, Targeted Protein Degradation,

CAMBRIDGE, United Kingdom — October 12, 2026 Amphista Therapeutics announced that the first patient has been dosed in its...